|
WO1985000831A1
(en)
|
1983-08-10 |
1985-02-28 |
Amgen |
Microbial expression of insulin-like growth factor
|
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
|
US5155038A
(en)
|
1990-02-22 |
1992-10-13 |
W. R. Grace & Co.-Conn. |
Use of thrombospondin to promote wound healing
|
|
DE69127749T2
(de)
|
1990-03-20 |
1998-04-16 |
The Trustees Of Columbia University In The City Of New York, New York, N.Y. |
Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
SE9101840L
(sv)
*
|
1991-06-14 |
1992-12-15 |
Kabi Pharmacia |
Ny medicinsk anvaendning
|
|
US5736363A
(en)
|
1991-07-29 |
1998-04-07 |
British Bio-Technology Limited |
IGF-II analogues
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
ES2174852T3
(es)
|
1992-08-26 |
2002-11-16 |
Celtrix Pharma |
Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
|
|
US5843780A
(en)
|
1995-01-20 |
1998-12-01 |
Wisconsin Alumni Research Foundation |
Primate embryonic stem cells
|
|
US5622932A
(en)
|
1995-05-05 |
1997-04-22 |
Eli Lilly And Company |
IGF-1 superagonists
|
|
GB9608130D0
(en)
|
1996-04-19 |
1996-06-26 |
Univ Sheffield |
Adam proteins and uses thereof
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
TWI233361B
(en)
|
2001-04-13 |
2005-06-01 |
Gen Hospital Corp |
Methods of preventing UVB-induced skin damage
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
CN101172091B
(zh)
|
2007-09-25 |
2011-04-27 |
北京美福源生物医药科技有限公司 |
含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
|
|
US7355018B2
(en)
|
2003-09-30 |
2008-04-08 |
Regeneron Pharmaceuticals, Inc. |
Modified IGF1 polypeptides with increased stability and potency
|
|
US7837993B2
(en)
|
2004-03-19 |
2010-11-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for regeneration of aged skeletal muscle tissues
|
|
AU2006203882B2
(en)
|
2005-01-07 |
2011-05-12 |
Regeneron Pharmaceuticals, Inc. |
IGF-1 fusion polypeptides and therapeutic uses thereof
|
|
EP2236153A3
(en)
*
|
2005-01-25 |
2012-08-22 |
Five Prime Therapeutics, Inc. |
Compositons and methods for treating cardiac conditions
|
|
US7521211B2
(en)
|
2005-04-05 |
2009-04-21 |
Regeneron Pharmaceuticals, Inc |
IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
|
|
EP2474318A1
(en)
*
|
2006-06-07 |
2012-07-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US9226965B2
(en)
|
2007-10-05 |
2016-01-05 |
U.S. Department Of Veterans Affairs |
Method and composition for treating heart failure
|
|
WO2009137721A2
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
KR20100119437A
(ko)
|
2009-04-30 |
2010-11-09 |
충북대학교 산학협력단 |
인슐린 유사 성장 인자 ⅱ를 이용하여 세포 분화를 조절하는 방법
|
|
US9493578B2
(en)
*
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
BR112012033214B1
(pt)
|
2010-06-25 |
2020-11-03 |
Shire Human Genetic Therapies, Inc. |
uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
|
|
WO2012037687A1
(en)
|
2010-09-23 |
2012-03-29 |
Angiochem Inc. |
Therapeutic polypeptides and uses thereof
|
|
WO2012140650A2
(en)
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
|
WO2013166156A2
(en)
|
2012-05-01 |
2013-11-07 |
The Johns Hopkins University |
Compositions and methods for treating or preventing osteoarthritis
|
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
WO2014082080A2
(en)
|
2012-11-26 |
2014-05-30 |
Callidus Biopharma, Inc. |
Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
|
|
ES2679374T3
(es)
|
2012-11-27 |
2018-08-24 |
Biomarin Pharmaceutical Inc. |
Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
|
|
SG11201503782PA
(en)
|
2012-12-18 |
2015-06-29 |
Novartis Ag |
Stabilized insulin-like growth factor polypeptides
|
|
US9605084B2
(en)
*
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014152440A2
(en)
|
2013-03-15 |
2014-09-25 |
Trustees Of Boston University |
Polymorphism of thrombospondin-1 as a biomarker for susceptibility to dry eye
|
|
US9758763B2
(en)
|
2013-05-29 |
2017-09-12 |
The Regents Of The University Of California |
Methods and compositions for somatic cell proliferation and viability
|
|
JP2016535080A
(ja)
|
2013-10-02 |
2016-11-10 |
ノバルティス アーゲー |
療法における使用のためのインスリン様成長因子模倣物
|
|
US10265372B2
(en)
|
2014-08-12 |
2019-04-23 |
The Regents Of The University Of California |
Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
|
|
MX2017004742A
(es)
|
2014-10-20 |
2017-07-20 |
Nestec Sa |
Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
|
|
US10654912B2
(en)
|
2015-09-08 |
2020-05-19 |
Jcr Pharmaceuticals Co., Ltd. |
Human serum albumin mutant
|
|
CA3000742A1
(en)
|
2015-10-02 |
2017-04-06 |
Silver Creek Pharmaceuticals, Inc. |
Bi-specific therapeutic proteins for tissue repair
|
|
CN109312338B
(zh)
*
|
2015-10-30 |
2022-09-27 |
爱迪塔斯医药公司 |
治疗单纯疱疹病毒的crispr/cas相关方法及组合物
|
|
EP3419651B1
(en)
*
|
2016-02-24 |
2023-10-25 |
BioMarin Pharmaceutical Inc. |
Improved naglu fusion protein formulation
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
CN107759697B
(zh)
|
2016-08-19 |
2023-03-24 |
安源医药科技（上海）有限公司 |
制备融合蛋白的方法
|
|
GB201620119D0
(en)
|
2016-11-29 |
2017-01-11 |
Pharmafox Therapeutics Ag |
Compounds
|
|
WO2018189661A2
(en)
|
2017-04-10 |
2018-10-18 |
Palti Yoram Prof |
Methods and compounds for treating diabetes
|
|
CN110997708A
(zh)
|
2017-04-27 |
2020-04-10 |
礼来公司 |
人bmp7蛋白的变体
|
|
US20190240156A1
(en)
|
2018-02-06 |
2019-08-08 |
Agency For Science, Technology And Research (A*Star) |
Therapeutic Compositions Comprising Mesenchymal Stem Cell Particles And Related Methods
|
|
EP3762505A4
(en)
*
|
2018-03-09 |
2021-12-01 |
Avrobio, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT FOR PARKINSON'S DISEASE
|
|
TW202344691A
(zh)
|
2018-04-30 |
2023-11-16 |
美商阿米庫斯醫療股份有限公司 |
基因治療構築體及使用方法
|
|
EP4606428A3
(en)
*
|
2018-06-27 |
2025-11-05 |
Juvena Therapeutics, Inc. |
Heparin-associated polypeptides and uses thereof
|
|
EP3897747A4
(en)
|
2018-12-19 |
2022-12-07 |
The Board of Trustees of the Leland Stanford Junior University |
BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS
|
|
EP3917539A4
(en)
*
|
2019-02-01 |
2022-11-23 |
Avrobio, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS
|
|
JP2022552254A
(ja)
|
2019-10-10 |
2022-12-15 |
アミカス セラピューティックス インコーポレイテッド |
バリアントｉｇｆ２構築体
|
|
WO2021133858A1
(en)
|
2019-12-24 |
2021-07-01 |
Juvena Therapeutics, Inc. |
Heparin-associated polypeptides and uses thereof
|
|
EP4081241A4
(en)
|
2019-12-24 |
2024-05-01 |
Juvena Therapeutics, Inc. |
REGENERATIVE POLYPEPTIDES AND USES THEREOF
|
|
EP4171658A4
(en)
|
2020-06-24 |
2025-04-09 |
Lycia Therapeutics, Inc. |
Modified viral compositions for viral transduction
|
|
US20220031812A1
(en)
|
2020-07-30 |
2022-02-03 |
Silver Creek Pharmaceuticals, Inc. |
Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders
|
|
PE20231680A1
(es)
|
2021-02-17 |
2023-10-19 |
Dr Falk Pharma Gmbh |
Anticuerpos anti-cd30l y usos de estos
|
|
EP4359425B1
(en)
|
2021-06-21 |
2026-08-05 |
Juvena Therapeutics, Inc. |
Igf2 fusion polypeptide and use in the treatment of muscular dystrophy, sarcopenia, cachexia, or muscle injury
|
|
EP4359430A4
(en)
|
2021-06-23 |
2025-07-16 |
Lycia Therapeutics Inc |
BIFUNCTIONAL COMPOUNDS CONTAINING IGF-2 POLYPEPTIDES
|
|
US20230405089A1
(en)
|
2022-06-17 |
2023-12-21 |
Juvena Therapeutics, Inc. |
Heparin-Associated Polypeptides and Uses Thereof
|